Welcome to our dedicated page for Thermogenesis Holdings news (Ticker: THMO), a resource for investors and traders seeking the latest updates and insights on Thermogenesis Holdings stock.
ThermoGenesis Holdings, Inc. (NASDAQ: THMO) drives innovation in automated cell therapy technologies, specializing in CAR-T manufacturing solutions and clinical biobanking systems. This page aggregates all official announcements, financial disclosures, and strategic developments for investors and industry professionals.
Access real-time updates on the CAR-TXpress platform advancements, facility expansions like the Sacramento CDMO complex with ISO 7 cleanrooms, and partnership announcements. Track quarterly financial results, leadership changes, and regulatory milestones impacting the cell therapy sector.
Key content includes earnings reports, product launch details, manufacturing capacity updates, and collaborations with biotech partners. The curated news feed enables efficient monitoring of THMO's transition from medical device specialist to full-service cell therapy CDMO.
Bookmark this page for streamlined access to verified information about ThermoGenesis' automated bioprocessing systems and cryopreservation technologies. Check regularly for developments affecting the $4.3B CAR-T market and broader cell therapy landscape.
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) reported a 13% increase in net revenues for 2022, reaching $10.5 million, driven by higher AXP disposable sales. However, gross profit fell to $2.7 million (26% of revenue), down from 38% due to increased manufacturing costs. The company reduced operating expenses by 15% to $7.2 million and R&D expenses by 25% to $1.7 million. Despite the improvements, a comprehensive net loss of $11.2 million was reported, with cash reserves down to $4.2 million. ThermoGenesis is transitioning to a CDMO model, launching 12 ReadyStart cGMP Suites projected to generate $10-$16 million annually.